Mentioned On
Episode Mentions
Pharma and BioTech Daily · Apr 30, 2026
AstraZeneca's £300M UK Investment Resumes Amid FDA Pilot | Pharma and Biotech Daily
“Acquired MLX Biosciences for $700M to develop new Tourette's syndrome therapy addressing limited treatment options”
FDA Real-Time Clinical Trial Review PilotAstraZeneca UK Investment and Drug PricingOncology Market Consolidation Strategy
View Analysis